Free nicotine replacement therapy programs vs implementing smoke-free workplaces: A cost-effectiveness comparison

American Journal of Public Health

Volumn 95, Issue 6, 2005, Pages 969-975

  Ong, Michael K ^a,b   Glantz, Stanton A ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HEALTH PROGRAM; NICOTINE REPLACEMENT THERAPY; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SMOKING; SMOKING CESSATION; UNITED STATES; WORKPLACE;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; FINANCING, GOVERNMENT; HEALTH PROMOTION; HUMANS; MIDDLE AGED; MINNESOTA; NICOTINE; QUALITY-ADJUSTED LIFE YEARS; SMOKING; SMOKING CESSATION; STATE GOVERNMENT; TOBACCO SMOKE POLLUTION; WORKPLACE;

EID: 19644398762     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2004.040667     Document Type: Article

References (42)

1. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation, Agency for Health Care Policy and Research, JAMA, 1997;278:1759-1766.
2. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, Md: US Dept of Health and Human Services, Public Health Service; 2000.
3. Zhu S-H, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med. 2002;347:1087-1093.
4. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour: systematic review BMJ. 2002;325:188.
5. Magzamen S, Glantz SA. The new battleground: California's experience with smoke-free bars. Am J Public Health. 2001;91:245-252.
6. Samuels B, Glantz SA. The politics of local tobacco control, JAMA. 1991;266:2110-2117.
7. Traynor MP, Begay ME, Glantz SA, New tobacco industry strategy to prevent local tobacco control. JAMA. 1993;270:479-486.
8. Glantz SA, Balbach ED. Tobacco War: Inside the California Battles. Berkeley, Calif; University of California Press: 2000.
9. Tsoukalas T, Glantz SA. The Duluth clean indoor air ordinance: problems and success in fighting the tobacco industry at the local level in the 21st century. Am J Public Health, 2003;93:1214-1221.
10. Drape S, Glantz SA. British Columbia capital regional district 100% smokefree bylaw: a successful public health campaign despite industry opposition, Tob Control. 2003;12:264-268.
11. Dearlove JV, Glantz SA. Boards of Health as venues for clean indoor air policy making. Am J Public Health. 2002;92:257-265.
12. Ibrahim JK, Tsoukalas TH, Glantz SA. Public health foundations and the tobacco industry: lessons from Minnesota. Tob Control. 2004:Sep;13(3):228-236.
13. White J, Bero LA. Public health under attack: the American Stop Smoking Intervention Study (ASSIST) and the tobacco industry. Am J Public Health. 2004;94:240-250.
14. Tsoukalas TH, Ibrahim JK, Glantz SA. Shifting Tides: Minnesota Tobacco Politics. San Francisco, Calif: Center for Tobacco Control Research and Education. University of California, San Francisco; 2003.
15. Minnesota, v Philip Morris, File No. C1948565 (Minn Dist Ct 1998), cert denied, 2000 Minn. LEXIS 27 (2000).
16. Bauld L, Chesterman J, Judge K, Pound E, Coleman T. Impact of UK National Health Service smoking cessation services: variations in outcomes in England. Tob Control. 2003;12:296-301.
17. Warden J. NHS to target smokers. BMJ. 1999;318:1096.
18. UK Department of Health. Smoking Kills: A White Paper on Tobacco. London, UK: The Stationery Office; 1998.
19. US Census. ST-EST2003-AS2001: Estimates of the Population by Selected Age Groups and Sex for the United States and States: July 1, 2001. Washington, DC: Population Estimates Branch, US Census Bureau; 2004.
20. Porter S, Jackson K, Trosclair A, Pederson LL. Prevalence of current cigarette smoking among adults and changes in prevalence of current and some day smoking-United States, 1996-2001. MMWR Morb Mortal Wkly Rep. 2003;52:303-307.
21. DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS. The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol. 1991;59:295-304.
22. Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. J Clin Psychopharmacol. 2002;22:487-495.
23. Blue Cross and Blue Shield of Minnesota, Minnesota Department of Health, Minnesota Partnership for Action Against Tobacco, University of Minnesota. Quitting Smoking, 1999-2003: Nicotine Addiction in Minnesota. Available at: http://repositories.cdlib.org/tc/surveys/mncessation. Accessed February 6, 2004.
24. National Health Insurance Survey. Atlanta, Ga: Centers for Disease Control and Prevention; 2000.
25. Pierce J P, Gilpin EA, Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002;288:1260-1264.
26. Behavioral Risk Factor Surveillance Survey. Atlanta, Ga: Centers for Disease Control and Prevention; 2000.
27. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994;343:139-142.
28. Keeler TE, Hu TW, Keith A, et al. The benefits of switching smoking cessation drugs to over-the-counter status. Health Econ. 2002;11:389-402.
29. Centers for Disease Control and Prevention. Smoking cessation during previous year among adults-United States, 1990 and 1991. MMWR Morb Mortal Wkly Rep. 1993;42:504-507.
30. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA. 1996;275:1247-1251.
31. Comuz J, Pinget C, Gilbert A, Paccaud F. Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol. 2003;59:201-206.
32. Medical Economics Company. Red Book. Montvale, NJ: Medical Economics; 2002.
33. Ong M, Lightwood JM, Glantz SA. Health and Economic Impacts of the Proposed Florida Smokefree for Health Initiative. San Francisco, Calif: Center for To bacco Control Research and Education, University of California San Francisco; 2002. Report No. FL2002.
34. Ong M, Glantz SA. Cardiovascular health and economic effects of smokefree workplaces, Am J Med. 2004;117:32-38.
35. Shopland DR, Gerlach KK, Burns DM, Hartman AM, Gibson JT. State-specific trends in smoke-free workplace policy coverage: the current population survey tobacco use supplement, 1993 to 1999. J Occup Environ Med. 2001; 43:680-686.
36. Gilpin EA, Emery SL, Farkas AJ. Distefan JM, White MM, Pierce JP. The California Tobacco Control Program. A Decade of Progress, Results from the California Tobacco Surveys, 1990-1998. La Jolla, Calif: University of California, San Diego; 2001.
37. Kennedy PW, DeVitto RA, How to Organize and Run a Successful Statewide Ballot Campaign. 2002 National Conference on Tobacco or Health. Available at http://colo4.ncth.confex.com/ncth/responses/2002/287.pdf. Accessed March 16, 2005.
38. Ibrahim JK, Glantz SA. Tobacco Policy Making in California 2001-2003: No Longer Finishing First. San Francisco, Calif: Center for Tobacco Control Research and Education, University of California, San Francisco; 2003.
39. Gerlach KK. Shopland DR, Hartman AM, Gibson JT, Pechacek TF. Workplace smoking policies in the United States: results from a national survey of more than 100000 workers. Tob Control. 1997;6:199-206.
40. Farrelly M, Evans W, Sfekas A. The impact of workplace smoking bans; results from a national survey. Tob Control. 1999;8:272-277.
41. Gold M, Siegel J, Russell L, Weinstein M, eds. Cost-Effectiveness in Health and Medicine. Oxford, UK: Oxford University Press; 1996.
42. Oster G, Huse DM, Delea TE, Colditz GA. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA. 1986;256:1315-1318.